Oblenio Bio Closes $62M Series B for Autoimmune T-Cell Engager

June 29, 2026

Fundraise Insider tracks newly funded startups each week and delivers verified B2B leads list of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Oblenio Bio, a biotechnology company based in Cambridge, Massachusetts, has closed an oversubscribed $62 million Series B financing. The round, announced on June 25, 2026, was led by Pfizer Ventures, with participation from new investors Deep Track Capital and GV, alongside Aditum Bio, the company’s founding and Series A investor.

Proceeds will fund the initial clinical development of LBL-051, the company’s tri-specific T-cell engager. The therapy is designed to achieve a broad reset of the immune system to treat patients with a range of refractory autoimmune diseases. The company plans to begin a first-in-human proof-of-concept study this year.

LBL-051 brings together three validated targets, BCMA, CD19, and CD3, and is engineered specifically for autoimmune patients.

The financing reflects growing investor interest in applying T-cell engager approaches, which were developed largely in cancer, to autoimmune disease.

You may also like

35 Sales Email Tips to Crush Your Sales Game

In today’s digital age, email remains one of the most effective tools for reaching out to potential customers and driving sales. However, crafting a successful sales email can be tricky, as you need […]

Recently Funded Startups Are A Great Sales Target. Here’s Why.

The startup industry has been growing at an unprecedented rate in recent years, with billions of dollars being poured into the sector every year. This growth has created an opportunity for businesses to […]

How to Identify Your B2B Target Audience: A Comprehensive Guide

For any business to succeed, it is essential to target the right audience. In B2B marketing, identifying your target audience is even more important, as it helps you focus your efforts and resources […]